Europe's Advertising Rules vs Big Pharma

Can Europe's Advertising Rules Stop Big Pharma's Marketing Gold Rush?

Marketing and Advertising

Novo Nordisk's immersive "obesity experience" tests European advertising rules as regulators struggle to enforce boundaries against billion-dollar drug campaigns.

European regulators crack down on pharmaceutical companies' obesity awareness campaigns disguised as direct-to-consumer promotion
Novo Nordisk launches immersive London exhibition coinciding with Wegovy pill launch, avoiding explicit drug mentions
Fines remain modest compared to blockbuster drug revenues, raising questions about enforcement effectiveness across the continent

Novo Nordisk has opened an immersive public exhibition in central London designed to reshape conversations around obesity while skirting Europe's strict advertising rules. The "Meet Me in the Middle" installation is a maze-like set-up that combines elements of escape rooms with videos and individual stories. It was launched at the South Bank with a view of the River Thames for two days from June 8. This act coincides with the launch of Wegovy, the latest weight-reducing drug by Novo, but the installation does not refer to the drug.

The concept of the maze is symbolic of the idea underlying the exhibition. It illustrates that weight loss is not an easy or simple process, and that many patients experience obstacles in their journey. Novo has publicly shared the results of a survey that indicate that 64% of more than 2,000 British obese people have had to deal with phases when there was no drop in weight, and that 82% of them got depressed during these periods.

The new installation has been completed in the midst of increasing concern from EU authorities who claim that medical promotions marry the public health promotion and direct marketing campaigns, which is considered illegal. For instance, the French ANSM has already fined Novo Nordisk and Eli Lilly for bringing out illegal obesity awareness campaigns. Similar investigations have opened across Europe, signaling a broader enforcement wave.

Novo's approach—deploying an experiential marketing strategy that educates without mentioning its product—represents a sophisticated evolution in pharmaceutical promotion strategies. By framing the exhibition as stigma-reduction and public health education rather than drug marketing, the company navigates technical compliance while creating brand awareness during a critical market launch window.

Business Honor is of the view that Novo Nordisk's experiential marketing strategy represents a sophisticated circumvention of Europe's direct-to-consumer advertising rules during obesity drug's critical market launch phase.